What Does Editas Medicine Do?

Total employees314
HeadquartersCambridge
Founded2013

Editas Medicine is a clinical-stage biotechnology company focused on translating the power and promise of genome editing technologies into a robust pipeline of treatments for people living with serious diseases around the world. Headquartered in Cambridge, MA, Editas Medicine is pioneering the development of both in vivo (directly in the body) and ex vivo (outside the body) CRISPR-based medicines. Their lead programs target severe hematologic diseases like sickle cell disease and beta-thalassemia, with ongoing research in other therapeutic areas including oncology and ocular diseases. The company aims to deliver durable, life-changing therapies by precisely editing DNA.

Where Is Editas Medicine's Headquarters?

HQ Function

The headquarters serves as the primary center for research and development, corporate operations, clinical development, and strategic decision-making, focusing on advancing CRISPR-based gene editing therapies.

Notable Features:

State-of-the-art laboratory facilities designed for gene editing research, process development, manufacturing sciences, and analytical capabilities. The building supports advanced scientific discovery, collaboration, and houses the company's leadership.

Work Culture:

Editas Medicine fosters a dynamic, science-driven, and collaborative work environment. The culture emphasizes innovation, a commitment to patients, scientific rigor, and teamwork, attracting talent passionate about pioneering new medicines.

HQ Significance:

Its Cambridge location (Kendall Square vicinity) provides unparalleled access to a rich ecosystem of world-class academic institutions, research organizations, a highly skilled talent pool, and venture capital, crucial for a leading-edge biotechnology company.

Values Reflected in HQ: The headquarters reflects Editas Medicine's core values of scientific excellence, patient focus, innovation, and integrity, providing an environment conducive to groundbreaking research and development of transformative therapies.

Location:

Editas Medicine's primary operational footprint, including research, development, and corporate functions, is centered in the United States (Cambridge, MA, and Boulder, CO). While direct office presence is US-based, the company's reach is global through its clinical trials, which may be conducted at sites in multiple countries. Editas Medicine also engages in global collaborations and partnerships to advance its mission of bringing gene editing therapies to patients worldwide.

Street Address:

11 Hurley Street

City:

Cambridge

State/Province:

MA

Country:

USA

Where Else Does Editas Medicine Operate Around the World?

Boulder, CO/USA

Address: 6100 Lookout Rd, Suite 100, Boulder, CO 80301

This location allows Editas Medicine to leverage the biotechnology and scientific talent pool in the Boulder/Denver metropolitan area and may support specific research programs, technical operations, or collaborations.

Buying Intent Signals for Editas Medicine

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Editas Medicine? Meet the Executive Team

As of April 2025, Editas Medicine' leadership includes:

Gilmore O’Neill, M.B., M.Med.Sc. - President and Chief Executive Officer
Erick J. Lucera, M.B.A., C.F.A. - Chief Financial Officer
Baisong Mei, M.D., Ph.D. - Chief Medical Officer
Linda C. Csellak, M.S., PMP - Chief Patient Officer and Head of External Affairs & Communications
Cristi L. Barnett, J.D. - Chief Legal Officer and Corporate Secretary
Bruce E. Eaton, Ph.D. - Chief Business Officer
Bernadette Connaughton, M.P.A - Chief Human Resources Officer

Who's Investing in Editas Medicine?

Editas Medicine has been backed by several prominent investors over the years, including:

The Vanguard Group, Inc.
BlackRock Inc.
State Street Corporation
Nikko Asset Management Americas, Inc.
Geode Capital Management, LLC
Fidelity Management & Research Company LLC (FMR LLC)

What Leadership Changes Has Editas Medicine Seen Recently?

Hire2
Exits0

Over the past 12 months (May 2023 - May 2024), Editas Medicine has strategically strengthened its executive leadership team with key appointments in legal and business development, underscoring its commitment to advancing its pipeline and corporate strategy. No major C-level departures resulting in immediate replacement announcements were noted in this period.

New Appointments:

Cristi L. Barnett, Cristi L. Barnett appointed as Chief Legal Officer and Corporate Secretary, bringing extensive legal expertise in the biopharmaceutical industry.
Bruce E. Eaton, Bruce E. Eaton appointed as Chief Business Officer to lead business development and corporate strategy.

What Technology (Tech Stack) Is Used byEditas Medicine?

Discover the tools Editas Medicine uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Editas Medicine Email Formats and Examples

Editas Medicine primarily uses the email domain @editasmed.com for its corporate communications. The most commonly observed email format is the employee's first initial followed by their last name.

firstinitiallast@editasmed.com

Format

jdoe@editasmed.com

Example

85%

Success rate

What's the Latest News About Editas Medicine?

Editas Medicine Press Release (GlobeNewswire)May 9, 2024

Editas Medicine Announces First Quarter 2024 Results and Business Update

Editas Medicine reported its financial results for the first quarter of 2024 and provided a business update, highlighting progress in its EDIT-301 program for sickle cell disease and beta-thalassemia, including patient dosing milestones and upcoming data readouts. The company reiterated its strategic priorities and pipeline advancement....more

Editas Medicine Press Release (GlobeNewswire)February 28, 2024

Editas Medicine Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

The company announced its financial results for Q4 and full-year 2023, along with updates on its clinical programs, particularly focusing on the advancement of EDIT-301 (reni-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia....more

Editas Medicine Press Release (GlobeNewswire)December 11, 2023

Editas Medicine Announces Positive Initial Data from the RUBY Trial of Renizgamagene Autogedtemcel (Reni-cel) in Patients with Severe Sickle Cell Disease and the EdiTHAL Trial in Patients with Transfusion-Dependent Beta Thalassemia

Editas Medicine shared encouraging initial safety and efficacy data from its Phase 1/2 RUBY trial for severe sickle cell disease and EdiTHAL trial for transfusion-dependent beta-thalassemia. The data showed successful engraftment of reni-cel and early indicators of clinical benefit, including increased fetal hemoglobin levels and improved anemia....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Editas Medicine, are just a search away.